- Home
- GRF vs MIRA Comparison
GRF vs MIRA Comparison
Compare GRF & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | MIRA |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 32.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GRF | MIRA |
|---|---|---|
| Price | $9.84 | $0.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 164.1K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $0.60 |
| 52 Week High | $11.85 | $2.45 |
Technical Indicators
Market Signals| Indicator | GRF | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 39.69 |
| Support Level | $9.66 | $0.60 |
| Resistance Level | $10.60 | $0.82 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 31.92 | 28.12 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.